Pronounced state-level variation in prescription cannabinoids to Medicaid patients

Abstract

Background: Dronabinol is approved for chemotherapy induced nausea as well as vomiting and HIV-induced anorexia, while cannabidiol is primarily approved for childhood epileptic disorders Lennox-Gastaut and Dravet syndrome. The use pattern for these prescription cannabinoids in the US is unknown. Methods: This study analyzed Medicaid claims and spending for dronabinol and cannabidiol prescriptions from 2016-2020. Results: Dronabinol prescriptions decreased by 25.3% from 2016 to 2020 while cannabidiol prescriptions increased by 16,272.99 % from 2018 to 2020. The spending on these drugs parallels that on their prescription trend with a 66.3% decrease in reimbursement for dronabinol ($5.7 million in 2020), whereas that of cannabidiol increased by +26,582.0% ($233.3 million in 2020). Dronabinol prescriptions in Connecticut were 136.4 times larger than New Mexico and 17 states had zero prescriptions. Idaho prescriptions, when corrected for number of enrollees, were 15.4-fold higher than Washington DC. Prescribing of dronabinol and cannabidiol did not differ significantly based on the whether the state had an active medical marijuana program. Conclusions: The prescriptions of pharmaceutical grade tetrahydrocannabinol were decreasing while cannabidiol was increasing. This study also identified pronounced state level variation in cannabinoid prescribing to Medicaid patients. Further research to identify the origins of these disparities is needed.

Competing Interest Statement

BJP was part of an osteoarthritis research team (2019-2021) supported by Pfizer and Eli Lilly. The other authors have no disclosures.

Funding Statement

Software used in this study was provided by National Institute of Environmental Health Sciences (T32 ES007060-31A1). BJP was supported by the Health Resources Services Administration (D34HP31025).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The IRBs of the University of New England and Geisinger approved this research as exempt.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

留言 (0)

沒有登入
gif